Showing 3311-3320 of 7283 results for "".
- Industry Responds to COVID-19: E.T. Browne Drug Co., Columbia University Medical Center, RealSelfhttps://practicaldermatology.com/news/industry-responds-to-covid-19-def-leo-pharma-dermyoung-coty/2460329/E.T. Browne Drug Co. The manufacturer of Palmer' Cocoa Butter Formula and Coconut Oil Formula skin and hair care products is now producing medical-grade hand sanitizer to address widespread supply shortages in the wake of COVID-19. Initial production of the disinfectant sanit
- Positive Phase 3 Results Reported for Medimetriks and Otsuka's AD Drughttps://practicaldermatology.com/news/positive-phase-3-results-reported-for-medimetriks-and-otsukas-ad-drug-1/2460322/Medimetriks Pharmaceuticals, Inc. and Otsuka Pharmaceuticals Co. Ltd.’s MM36 (difamilast) performed well in two Phase 3 Japanese clinical trials in adult and pediatric atopic dermatitis (AD) patients. Difamilast is a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibit
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- Destiny Pharma and MedPharm Complete Initial Phase of Development Projecthttps://practicaldermatology.com/news/destiny-pharma-and-medpharm-complete-initial-phase-of-development-project/2460318/Destiny Pharma and MedPharm have completed the initial phase of their project to develop new topical formulations of Destiny’s novel XF‐platform drugs. Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations w
- Owing to the Advent of New Treatments, Melanoma Death Rates Drophttps://practicaldermatology.com/news/owing-to-the-advent-of-new-treatments-melanoma-death-rates-drop/2460312/Melanoma is killing the fewest Americans in decades, according to a study in the American Journal of Public Health. Death rates for metastatic melanoma among white Americans climbed 7.5 percent between 1986 and 2013, but then dropped by nearly 18 percent over the next thre
- International Psoriasis Council Offers Guidance on Managing COVID-19 in People with Psoriasishttps://practicaldermatology.com/news/international-psoriasis-council-offers-guidance-on-managing-covid-19-in-people-with-psoriasis/2460302/Psoriasis patients diagnosed with COVID-19 (coronavirus disease) should immediately discontinue or postpone immunosuppressant medications, guidance from the International Psoriasis Council (IPC) states. The group cites current guidance from the European Dermatology Forum and the American Academy
- Study: Mohs Scars from Facial Skin Cancers Longer than Patients Expecthttps://practicaldermatology.com/news/study-mohs-scars-from-facial-skin-cancers-longer-than-patients-expect/2460301/Scars from Mohs micrographic surgery for facial skin cancers may be longer than patients expect, according to new research published in JAMA Network Open. In this cross-sectional study of 1
- New from Lumenis: Meet the Stellar M22 Platformhttps://practicaldermatology.com/news/new-from-lumenis-meet-the-stellar-m22-platform/2460300/Lumenis Ltd. is launching the Stellar M22, a multi-application platform that builds on the heritage of the M22 by adding even more bells and whistles. The new Stellar M22 is now available in the USA and Europ
- Study: DermTech’s Non-Invasive Gene Expression Testing Improves Early Melanoma Detectionhttps://practicaldermatology.com/news/study-dermtechs-non-invasive-gene-expression-testing-improves-early-melanoma-detection/2460297/A large registry study confirms that DermTech Pigmented Lesion Assay can reduce unnecessary biopsies by up to 90 percent, lower healthcare costs, and rule out melanoma. “The DermTech PLA helps clinicians employ precision dermatology and harness genomics technology to detect malign
- First Patient Enrolled in Avita Medical’s Pivotal Study Evaluating Recell System for Soft Tissue Reconstructionhttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-medicals-pivotal-study-evaluating-recell-system-for-soft-tissue-reconstruction/2460294/Avita Medical Limited enrolled the first patient in a study evaluating the Recell System for Soft Tissue Reconstruction at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. The prospective multi-center trial of at least 65 patients will compare the clinical per